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Multiple Sulfatase Deficiency (MSD; OMIM 272200) is a rare autosomal recessive inborn error of metabolism caused
by mutations in the sulfatase modifying factor 1 gene, encoding the formylglycine-generating enzyme (FGE), and
resulting in tissue accumulation of sulfatides, sulphated glycosaminoglycans, sphingolipids and steroid sulfates. Less
than 50 cases have been published so far. We report a new case of MSD presenting in the newborn period with
hypotonia, apnoea, cyanosis and rolling eyes, hepato-splenomegaly and deafness. This patient was compound
heterozygous for two so far undescribed SUMF1 mutations (c.191C > A; p.S64X and c.818A > G; p.D273G).
Keywords: Multiple sulfatase deficiency, MSD, SUMF1 geneIntroduction
Multiple Sulfatase Deficiency is a rare autosomal reces-
sive inborn error of metabolism characterized by the
defective activity of all known sulfatases [1]. It is caused by
mutations in the sulfatases- modifying factor 1 gene
encoding the FGE. Sulfatases are a family of enzymes that
catalyze the hydrolysis of ester sulfates, including glycos-
aminoglycans, sulfolipids and steroid sulfates. These pro-
teins share high amino acid sequence homology. However
they show different sub-cellular localization and substrate
specificity [1,2]. The SUMF1 gene encodes for a sulfatase-
modifyng factor, which converts a highly conserved cysteine
within the sulfatase catalytic domain into Cα- formylglycine
[3]. It has been shown that this post-translational modi-
fication is both an essential and limiting factor for the
enzymatic activity of sulfatases [4]. The SUMF1 gene is
located on chromosome 3p26. It spans 105 kb and the
coding sequence is distributed over 9 exons. The cDNA for
human FGE is predicted to encode a protein of 374 resi-
dues. The protein contains a cleavable signal sequence
of 33 residues, which indicates translocation of FGE* Correspondence: garavelli.livia@asmn.re.it
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unless otherwise stated.into the endoplasmatic reticulum, and contains a single
N-glycosylation site at Asn-141 [5]. The middle part of
FGE (residues 179–308 in human FGE) is represented by
a tryptophan-rich subdomain. The C-terminal subdomain
(residues 327–366 in human FGE) is the most highly
conserved sequence within the FGE family.
FGE post translationally activates all newly synthesized
sulfatase by generating the catalytic residue formylgly-
cine. Impaired FGE function leads to a reduction in
sulfatase activities. It has been proved that variability of
the clinical phenotype depends on both residual FGE ac-
tivity as well as protein stability [6]. MSD is characterized
by features of mucoplysaccharidosis and metachromatic
leukodystrophy including neurologic deterioration and
development delay, gargoyle-like features, visceromegaly,
heart involvement, ichthyosis, hydrocephaly, cloudy
corneal and skeletal anomalies [7]. According to the age of
onset, very neonatal, late infantile (severe or LIS and mild
or LIM) and rare juvenile (mild) disease subtypes can be
distinguished [8].
We described a clinical case of a girl with a neonatal
form of MSD, presenting typical findings of the disease.
She was compound heterozygous for two so far undescribed
SUMF1 mutations (c.191C >A; p.S64X and c.818A > G;
p.D273G).l. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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The girl is the first child of healthy, non-consanguineous
parents. She was born by vaginal delivery at week 40 with
birth weight of 2,815 g, length 46 cm, and head circumfer-
ence 32 cm. APGAR scores were 9/10. At 20 hours of life
she was transferred to our Neonatal Intensive Unit be-
cause of the appearance of rolling eyes followed by
episodes of apnoea with cyanosis and hypotonia, for which
a treatment with phenobarbital was installed. At that time,
physical examination showed coarse facial features, high-
arched, thick eyebrows, bulbous nasal tip, micrognathia,
posteriorly rotated ears with attached lobes, flared thorax,
inverted nipples, hepatosplenomegaly, broad thumbs, mild
ichthyosis and muscular hypotonia. (Figure 1A, B, C, D).
At 11 days of life she presented two episodes of obstruct-
ive respiratory arrest after stridor, treated with ventilation.
The otolaryngologist’s evaluation revealed the presence of
a cystic formation of the vallecula, which was removed
surgically with resolution of the episodes of apnoea.
Because of the coarse facial features, hypertrichosis,
and hepatosplenomegaly, a lysosomal storage disorderFigure 1 Phenotype. A: coarse face, high-arched, thick eyebrows,
bulbous nasal tip and mild ichthyosis. B: micrognathia, posteriorly rotated
ears with attached lobes. C: abdominal ichthyosis. D: ichthyosis of the
lower limb and feet.was considered. There was an increased urinary excretion
of glycosaminoglycans (1101 μg/mg creatinine; normal
range, 30–200), with chondroitin sulfate (+++), dermatan
sulfate (+++) and heparan sulfate (++) on electrophoresis.
Enzyme activitiy testing in leucocytes showed deficiency
of arylsulfatase A (0.0 nM/mg/h; n.v. 40–270), arylsulfa-
tase B (0.0 nM/mg/h; n.v. 70–126), iduronate sulfatase
(0.9 nM/mg/4 h; n.v. 51–123) and galactose 6 sulfatase
(0.6 nM/mg/17 h; n.v.20-27). This pattern was diagnostic
of Multiple sulfatase deficiency (MSD). Molecular analysis
of the gene SUMF1 revealed two so far undescribed
heterozygous mutations: c.191C > A s. S64X in exon 1
and c.818A >G p.D273G in exon 6. The first heterozygous
mutation was also demonstrated in the girl’s mother, while
the second one was identified in the girl’s father.
The karyotype was normal, 46,XX. The echocardiography
and EEG were normal; abdominal ultrasound showed
hepatomegaly; brain magnetic resonance imaging (MRI)
showed dilated lateral ventricles with an enlarged cisterna
magna, demyelination of the white matter, partial corpus
callosum hypoplasia with hypothrophy of the splenium
and dismorphism of the hippocampum. Skeletal radio-
graphy revealed a pattern of dysostosis multiplex with
hypoplasia of L2, lumbar kyphosis and platyspondyly of
the cervical vertebral bodies; broad ribs; broad and hypo-
plastic first metacarpals, pointing of the second and
third metacarpals, irregularity of the distal radial and
ulnar metaphysis (Figure 2A, B, C, D). The ABR examin-
ation showed mild hypoacusia.
The child presented global developmental delay: could
hold head up only at the age of 10 months, at the age of
12 months she was still hypotonic, with limited and
jerky movements and it was impossible to meet her gaze.
She developed dorso-lumbar kyphosis and owing to L2
hypoplasia she had to wear a orthopaedic corset.
She was seen again in our Clinical Genetics Unit at
24 months of age. Her head circumference was 45 cm
(50th centile), length 66 cm (<3rd centile), and weight
6.406 Kg (<<3rd centile). Her psychomotor development
was severely delayed and she uttered no words. At the
age of 24 months she could not sit up unaided.
Discussion
Multiple sulfatase deficiency is a rare autosomal recessive
inborn error of metabolism affecting post-translational ac-
tivation of sulfatases by the formylglycine generating en-
zyme (FGE). Due to mutations in the encoding SUMF1
gene, FGE’s catalytic capacity is impaired, resulting in
reduced cellular sulfatase activities [9]. More than 30
different SUMF1 mutations are known, most of them mis-
sense mutations that affect stability and residual molecular
activity of mutant FGE, which both determine MSD
disease severity [10]. A variable residual activity of the
different sulfatases has been described [1,11].
Figure 2 X-Rays. A: broad and hypoplastic first metacarpals, pointing of the second and third metacarpals, irregularity of the distal radial and
ulnar metaphysis. B: platyspondily of the cervical vertebral bodies. C: hypoplastic vertebral body of L2, lumbar kyphosis. D: broad ribs.
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residual activity and stability of FGE variants with the
clinical presentation of selected MSD patients. Patients with
drastic impairments of both FGE stability and residual
enzyme activity displayed the most severe clinical pheno-
type whereas the mildest phenotype was associated with the
highest residual FGE activity among the studied variants.
It is now possible to establish a genotype/phenotype
correlation for MSD and to roughly predict the clinical
course for patients with the studied SUMF1 mutations.
Missense mutations affecting crucial functional or struc-
tural residues in FGE, as well as nonsense ones, will cause
severe forms of the disease, whereas missense mutations
not fully abrogating a functional conformation of the FGE
protein will lead to attenuated forms [6].
Different types of MSD can be distinguished according
to the age of onset: neonatal, late infantile (0 to 2 years,
severe or LIS and mild or LIM), and rare juvenile (2 to
4 years, mild) [8].
The clinical picture of MSD combines symptoms of
the different sulfatase deficiencies. Patients show neuro-
logical deterioration and a neurodegenerative course of
disease similar to metachromatic leukodystrophy. Develop-
ment delay, dysmorphism and organomegaly are present
as found in various mucopolysaccharidoses [6]. Skeletal
abnormalities remind one of Chondrodysplasia punctata
type 1 and skin changes of X-linked ichthyosis [1].
The onset of symptoms in early infancy is associated
with poor chances of survival; conversely, when features
of the disease appear in late infancy, patients survive
longer.
In general it is rare to carry out a diagnosis of storage
disease in newborns apart from I-cell disease also known
as mucolipidosis II, which is a condition with a severeclinical course, typical radiological aspects and fibroblast
inclusions. Other symptoms include hyperplastic gums,
thoracic deformities and congenital hip dislocation which
are evident in newborn age. In the other storage diseases
the symptoms are not so evident in the newborn age.
The diagnosis of MSD may not be simple due to the
rarity of the condition: in our case the features which led
us to suspect the diagnosis were the MPS-like phenotype,
the radiological signs compatible with “dysostosis multi-
plex” and especially the cutaneous features. The child had
no signs of chondrodysplasia punctata, in particular no
epiphyseal stippling.
Indeed the presence of ichthyosis can be a very useful
indicator in identifying the condition and can be the best
marker of the disease in newborns.
Our patient had typical features of neonatal MSD in-
cluding neonatal hypotonia, coarse face, mild deafness,
visceromegaly, hypoplastic vertebral bodies and delayed
psychomotor development.
It was demonstrated that the phenotypic outcome de-
pends on both residual FGE activity as well as protein
stability [6]. Another neonatal case was described which
showed all the clinical symptoms of the condition and a
quick worsening course of the disease: he presented two
nonsense mutations leading to almost fully abrogated
FGE activity, highly unstable FGE protein and nearly
undetectable sulfatase activity [6]. Our case presents a
missense mutation along with a nonsense mutation.
In fact we have identified two so far undescribed SUMF1
mutations (c.191C >A; p.S64X and c.818A >G; p.D273G),
resulting in a severe clinical phenotype with early onset,
but which allow survival beyond one year of life, in con-
trast with what has been reported in literature up to this
point. She has a serious clinical aspect, but probably less
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the age of 2 years.
MSD is still an untreatable disease. Thus, potential
treatment approaches, and also genetic counselling,
directly depend on thorough analyses of the functional
consequences of human SUMF1 mutations on the clinical
and biochemical phenotype.
Understanding better the molecular mechanism at the
root of this condition could aid the identification of the
most appropriate therapeutic approach of MSD in the
near future.
Conclusion
In conclusion, our patient illustrates well the main clinical
features to suspect this condition in the newborn age,
ichthyosis in particular, the wide spectrum of clinical
manifestations and biochemical abnormalities of this rare
disease. This case serves to highlight the importance of
full and detailed evaluation of all patients with rare dis-
orders and the need for continued updates of suggested
surveillance for these diseases.
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